backBackground
On July 13, 2026, the U.S. Food and Drug Administration (“FDA” or “Agency”) finalized its guidance on “Psychedelic Drugs: Considerations for Clinical Investigations,”1 FDA, Guidance for Industry, Psychedelic Drugs: Considerations for Clinical Investigations (July 13, 2026), https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations [hereinafter “2026 Final Guidance”]. replacing the June 2023 draft guidance.2 FDA, Draft Guidance for Industry, Psychedelic Drugs: Considerations for Clinical Investigations (June 23, 2023), https://web.archive.org/web/20251214083627/https:/www.fda.gov/media/169694/download [hereinafter “2023 Draft Guidance”].
The final guidance reads like an approval-readiness document, targeting New Drug Application (“NDA”)-stage considerations, such as abuse potential assessments, scheduling proposals, nonclinical and clinical study considerations, and postmarketing requirements. The Agency actively encourages sponsors to engage with FDA early in the clinical trial design development process and to propose novel methodologies, which could shape regulatory precedent. Concurrent with issuing the guidance, FDA also announced a public hearing on the potential future therapeutic use of psychedelic drugs, to be held on September 14, 2026.3 FDA, Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing (updated July 13, 2026), https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026.
The final guidance follows Executive Order 14401, which declared accelerating psychedelic drug approvals a national priority; directed FDA breakthrough therapy vouchers, Right to Try pathways, and $50 million in research funding; and expedited Drug Enforcement Administration (“DEA”) rescheduling review for Schedule I substances completing Phase 3 trials for serious mental health disorders.4See Exec. Order No. 14401, Accelerating Medical Treatments for Serious Mental Illness, (Apr. 18, 2026), https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/. Collectively, these actions signal that the Trump Administration is prioritizing innovation and access to these promising therapies, while continuing to expect rigorous evidence of their safety and effectiveness to support FDA approval.
New Rigor Under the “Adequate and Well-Controlled” Standard
FDA’s guidance observes that psychedelics produce “intense perceptual changes,” which create heightened risk of “functional unblinding” of patients, therapists, monitors, and raters, particularly when an inert placebo is used as the control.52026 Final Guidance at 9. To address this challenge, FDA recommends a menu of bias-mitigation tools, including use of blinded central raters and blinding and expectancy questionnaires to address potential subjective bias. FDA also “encourages the consideration of innovative approaches for control groups”6 Id. at 9. and recommends “[c]omplementary trial designs across phases 2 and 3,”7Id. at 10. potentially requiring multiple confirmatory trials with distinct designs, substantially increasing cost and timelines. Notably, FDA emphasizes that “[s]tudy results should be strongly persuasive and robust across study endpoints to overcome biases.”8Id. at 9–10 (emphasis added). This “strongly persuasive” language, absent from the 2023 draft, essentially raises the efficacy bar for studies that aim to provide substantial evidence of effectiveness to support FDA approval.
The Durability “Mandate”: 12-Week Endpoint Plus 12-Month Blinded Follow-Up
Acknowledging that psychedelics are being evaluated for chronic conditions like major depressive disorder and post-traumatic stress disorder (“PTSD”), the guidance indicates that FDA is unlikely to consider a single dosing session sufficient to demonstrate efficacy for chronic conditions. Reflecting the Agency’s concerns about durability and expectancy effects, FDA recommends:
- 12-week endpoint: Before an initial application for a product intended for the treatment of a chronic illness such as PTSD or major depressive disorder, sponsors should evaluate with a double-blind design the effect of treatment at 12 weeks.
- Continued monitoring: Sponsors should continue to follow subjects beyond the Week 12 endpoint to monitor for symptom recurrence or, potentially, the need for repeat dosing.
- 12-month endpoint: FDA describes the “most informative clinical trial design” as one that incorporates blinded long-term follow-up—typically 12 months—with prespecified criteria for retreatment. These criteria should consider symptom ratings as well as whether the participant seeks additional treatment outside the study.
- Characterizing dose intervals: If data suggest that re-administration on a regularly scheduled basis is warranted, the recommended interdose interval for maintenance of effect should be studied; it may be reasonable to conduct studies of specific maintenance treatment paradigms in the postmarketing period.9Id. at 10.
The Public Health Benefit-Risk Framework Applies an Established but High Controlled-Substance Standard
Significantly, “FDA may consider the public health effects of the drug as part of the overall benefit-risk assessment,” including “its potential effect on risks that are related to nonmedical use, substance use disorder, accidental exposure, and overdose for patients and the broader population.”102023 Draft Guidance at 11; 2026 Final Guidance at 13.
FDA has explained its risk-benefit assessment for controlled substances incorporates these broader public health risks, and FDA has previously considered public health factors in other settings: withdrawal of the original form of extended-release oxycodone based on population-level misuse; weighing disease transmission risks in vaccine reviews; and considering factors beyond clinical trial populations when requiring certain Risk Evaluation and Mitigation Strategies (“REMS”).11See FDA, Guidance for Industry, Benefit-Risk Assessment for New Drug and Biological Products 5 (Oct. 2023), https://www.fda.gov/media/152544/download; FDA, Guidance for Industry, Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework 2 (May 2026), https://www.fda.gov/media/128150/download (“FDA assesses risks and benefits of all drugs in the context of the use indicated in the labeling. However, because of the widespread misuse and abuse of prescription opioid analgesic drugs, for this class of drugs, FDA also considers the broader public health effect of opioid analgesic drugs; this involves consideration of the risks related to misuse, abuse, opioid use disorder, accidental exposure, and overdose, for both patients and others.”); 21 U.S.C. § 355-1.
Retaining population-level public health analysis in the final guidance underscores FDA’s cautious posture. While this framework is not novel, its application here is consequential: FDA is reserving a basis to deny approval even if individual-level efficacy is demonstrated—a standard that was developed in part as a post-market response to the opioid crisis.
The 2023 draft guidance framed REMS as an exception, noting “for the majority of drugs, routine risk mitigation measures . . . are sufficient” and only “in some cases” might FDA “consider” whether a REMS is necessary.122023 Draft Guidance at 10–11. The 2026 final guidance drops this framing, stating “the Agency anticipates that additional assessments of safety may be needed in the postmarketing setting,” directing sponsors to “consider the potential need for a [REMS].”132026 Final Guidance at 12. This recalibration, paired with language addressing risks to “patients and nonpatients” and new “formal driving study” recommendations, signals that FDA views post-approval risk management as highly likely for psychedelics.14Id. at 12–13.
Requiring Adverse Event Documentation of “Non-Adverse” Effects Is a Scheduling Strategy
The final guidance provides that “[s]ome expected psychoactive effects such as euphoria, hallucinations and other perceptual distortions, and alterations in cognition should also be recorded as AEs [adverse effects] for psychedelic drugs given their association with abuse potential, even if subjects do not describe these effects as adverse,” and even if “they are hypothesized to be associated with the therapeutic response.”15Id. at 8.
By creating an expectation that these subjective effects be captured as adverse events regardless of subject perception, FDA is building an abuse-potential dataset that DEA may use to justify controlled-substance scheduling post-approval. Psychedelic drugs will likely remain tightly scheduled even after marketing authorization, impacting prescribing, distribution, and commercial viability.
Acceleration Opportunities for Well-Prepared Sponsors
Although the final guidance sets a high evidentiary bar, it offers genuine acceleration opportunities for sponsors who employ novel methodologies, leverage existing data, and isolate their drug’s contribution to efficacy.
Innovative methodologies. The final guidance “encourages the consideration of innovative approaches for control groups”—language absent from the 2023 draft—and explicitly accepts “new approach methodologies” and computational modeling tools as supportive data.16Id. at 4, 8.
Leveraging existing data and engaging FDA’s Controlled Substance Staff. The final guidance encourages sponsors to engage FDA on abuse potential assessment “early in the IND stage” and request comments from CDER’s Controlled Substance Staff.17Id. at 9. FDA notes “a human abuse potential study may not be scientifically necessary . . . when the subjective effects predictive of abuse are well-characterized from extensive clinical studies and robust epidemiological data exist.”18Id. at 7. Similarly, standard animal toxicology may be unnecessary if “adequate human exposure” exists.19Id. at 4.
Sponsors proactively presenting abuse potential data may influence scheduling upon approval. For compounds with substantial published literature (psilocybin, MDMA, LSD), well-assembled literature packages may reduce NDA components substantially.
Isolating the drug signal. The guidance notes “the contribution of the psychotherapy component to any efficacy observed with psychedelic drug treatment has not been characterized,”20Id. at 11. and sponsors should describe their planned treatment paradigm, including whether it pairs administration with psychotherapy. Sponsors demonstrating efficacy without mandating psychotherapy will have broader labeling and simpler distribution.
These acceleration opportunities could enable well-known compounds to move faster and cheaper than novel molecules. Sponsors who successfully propose innovative methodologies and leverage existing data will define regulatory templates going forward.
Key Takeaways
The final guidance signals that FDA intends psychedelic approvals to proceed on terms that require rigorously designed programs. To maximize opportunities for successful development, sponsors should:
- Engage FDA and DEA early. The guidance’s invitations to discuss trial designs, abuse potential plans, and scheduling proposals are an opportunity for sponsors to inform and shape psychedelic drug approval precedent. Early engagement also will allow anticipation of specific safety considerations, at least some of which are described in the guidance.
- Build for durability and plan for REMS programs. Sponsors targeting chronic illnesses should anticipate long-term follow-up, REMS programs, and other post-market safety requirements.
- Leverage acceleration pathways. For well-known compounds, assembling published literature early may eliminate or reduce nonclinical and abuse potential studies. Sponsors isolating drug effects from psychotherapy may be rewarded with broader labeling.
For questions or tailored regulatory strategy support, our team stands ready to assist.